FINWIRES · TerminalLIVE
FINWIRES

最新消息:澳洲國民銀行增加撥備以因應中東衝突的影響;股價下跌4%。

-- (更新:在標題和最後一段中新增股票走勢資訊) 澳洲國民銀行(ASX:NAB)週一向澳洲證券交易所提交的文件顯示,由於提列撥備以反映中東衝突帶來的風險,預計上半年將提列7.06億澳元的信貸減損準備。 該銀行還計劃對其上半年股息再投資計畫進行折價和部分承銷,並已調整其軟體資本化政策,以適應快速技術變革的環境。 該銀行表示,前瞻性集體撥備淨增加3億澳元,其中包括與經濟調整相關的1.52億澳元增加,為應對可能受燃料供應和成本問題影響的行業潛在壓力而增加的2.01億澳元前瞻性調整,以及5300萬澳元的前瞻性調整釋放。 截至3月,該公司集體撥備與信用風險加權資產的比率預計為1.35%,高於2025年12月的1.31%,預計相關撥備費用為4.06億澳元。 該公司表示,由於第二財季利率波動和紐西蘭元走弱,加上撥備增加,截至3月31日,該行的普通股一級資本充足率下降了約20個基點。該行預計,計入股利再投資計畫1.5%的折扣後,其備考集團普通股一級資本充足率將超過12%。 該行表示,旨在加強資本狀況和資產負債表的各項舉措預計將在下半年籌集至多18億澳元,並使普通股一級資本充足率提高至多約40個基點。 澳洲國民銀行將於5月4日公佈半年業績,該行確認2026財年現金營運支出成長率將低於4.6%。 該行股價在周一的交易中下跌約4%。

Related Articles

Asia

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

Clinuvel Pharmaceuticals (ASX:CUV) is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.The company said on Friday that the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a "totality of evidence" regulatory approach.Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.

$ASX:CUV
Asia

ASX Preview: Australian Shares Set to Open Flat on Stalled US-Iran Talks; Origin Energy Reports Lower March Quarter Production

Australian shares are set to open flat on Monday, as oil prices climbed almost 2% following stalled US-Iran peace negotiations and restricted flows through the Strait of Hormuz, tightening global supply and pushing Brent crude above $107 a barrel.On April 25, the S&P 500 and the Nasdaq Composite rose 0.8% and 1.6%, respectively, while the Dow Jones Industrial Average fell 0.2%.In the macroeconomy, investors are eyeing the release of Australia's consumer price index report on Wednesday.In corporate news, Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.IperionX's (ASX:IPX) titanium powder production operations in Virginia, US, transitioned to an around-the-clock production schedule during the March quarter, advancing from commissioning to continuous operations, according to a Monday filing with the Australian bourse.Australia's benchmark index fell 0.1% or 6.9 points to close at 8,786.50 on April 24.

$^AXJO$ASX:IPX$ASX:ORG
Asia

Cobre Appoints Chief Financial Officer

Cobre (ASX:CBE) has appointed Kaveen Bachoo as chief financial officer, effective April 28, according to a Monday filing with the Australian bourse.Bachoo has over 20 years of finance leadership experience in the mining sector, including executive positions at Glencore.

$ASX:CBE